
FDA’s New ANDA Pilot: A Win for U.S. Manufacturing
FDA’s ANDA Prioritization Pilot: What It Means for U.S. Generics and CDMOs
Read MoreDigital Confidence: Building Trust in Sterile Manufacturing
The sterile injectable space is evolving quickly, and capacity and compliance alone are no longer en...
Pharma Tariffs Push for U.S. Production
What the New Pharma Tariff Means for CDMOs and Sterile Injectables The U.S. just announced a propose...
Bigger and Built to Deliver.
In sterile injectable manufacturing, growth isn’t optional, it’s key.
American Injectables Announces Key Leadership Appointments to Drive Future Growth
American Injectables, a leading contract development and manufacturing organization (CDMO) specializ...
American Injectables Earns FDA Approval
BROOKSVILLE, FL (January 9, 2025) — American Injectables, a contract development and manufacturing o...
A Business-Minded Guide to Injectable Solutions and Market Trends
You don’t need a PhD in biochemistry to work in the pharmaceutical industry. However, understanding ...
Pharmaceutical Data Integrity: Protecting Your Branded Formulation
Imagine spending years and hundreds of thousands of dollars on a formulation, only to have it compro...
Special Considerations for Developing Parenteral Formulations
Compared to oral and transdermal medicine, parenteral formulations are potent and fast-acting. With ...
Strengthening the Pharmaceutical Supply Chain: It Starts With Formulation
The effects of supply chain issues are often most noticeable at the consumer level, manifesting as p...